MediWound (NASDAQ:MDWD) Share Price Crosses Below 200 Day Moving Average – Should You Sell?

MediWound Ltd. (NASDAQ:MDWD) shares crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $17.61 and traded as low as $16.15. MediWound shares last traded at $16.25, with a volume of 53,976 shares.

Analyst Ratings Changes

A number of research firms have issued reports on MDWD. Wall Street Zen downgraded MediWound from a “hold” rating to a “strong sell” rating in a report on Saturday, March 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, MediWound has a consensus rating of “Hold” and an average target price of $35.00.

MediWound Trading Down 2.3%

The firm has a fifty day moving average of $16.86 and a 200 day moving average of $17.59. The company has a market capitalization of $210.87 million, a P/E ratio of -7.81 and a beta of 0.21.

MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Saturday, February 14th. The biopharmaceutical company reported ($0.56) EPS for the quarter. The business had revenue of $1.87 million during the quarter. MediWound had a negative return on equity of 65.79% and a negative net margin of 140.80%. Sell-side analysts anticipate that MediWound Ltd. will post -2.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Meitav Investment House Ltd. boosted its position in MediWound by 825.7% in the third quarter. Meitav Investment House Ltd. now owns 291,618 shares of the biopharmaceutical company’s stock worth $5,241,000 after purchasing an additional 260,116 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd purchased a new position in MediWound in the third quarter worth about $1,042,000. Menora Mivtachim Holdings LTD. boosted its position in MediWound by 348.8% in the third quarter. Menora Mivtachim Holdings LTD. now owns 78,539 shares of the biopharmaceutical company’s stock worth $1,415,000 after purchasing an additional 61,039 shares during the last quarter. Rosalind Advisors Inc. boosted its position in MediWound by 84.0% in the third quarter. Rosalind Advisors Inc. now owns 749,054 shares of the biopharmaceutical company’s stock worth $13,498,000 after purchasing an additional 341,993 shares during the last quarter. Finally, ARK Investment Management LLC boosted its position in MediWound by 2.3% in the third quarter. ARK Investment Management LLC now owns 96,879 shares of the biopharmaceutical company’s stock worth $1,746,000 after purchasing an additional 2,209 shares during the last quarter. 46.83% of the stock is owned by hedge funds and other institutional investors.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.